Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

66. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin
system. Physiol Rev 1992; 72:165–229.
67. Leathwood PD. Tryptophan availability and serotonin synthesis.
Proc Nutr Soc 1987; 46:143–56.
68. Hamon M, Bourgoin S, Artaud F et al. The respective roles of
tryptophan uptake and tryptophan hydroxylase in the regulation
of serotonin synthesis in the central nervous system.
J Physiol (Paris) 1981; 77:269–79.
69. Boadle-Biber MC. Regulation of serotonin synthesis. Prog
Biophys Mol Biol 1993; 60:1–15.
70. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological
dependence on plasma tryptophan levels. Science 1971;
173:149–52.
71. Fernstrom JD. Role of precursor availability in control of
monoamine biosynthesis in brain. Physiol Rev 1983; 63:484–546.
72. Aghajanian GK, Sprouse JS, Rasmussen K. Electrophysiology of
central serotonin receptor subtypes. In: Saunders-Bush E, ed.
The Serotonin Receptors. Clifton, NJ: The Humana Press;
1988:225–52.
73. Stahl SM. Depression and bipolar disorders. In: Grady MM, ed.
Essential Psychopharmacology: Neuroscientific Basis and Practical
Applications, 2nd edn. New York: Cambridge University Press;
2000:135–97.
74. White KJ, Walline CC, Barker EL. Serotonin transporters: implications
for antidepressant drug development. AAPS J 2005;
7:E421–33.
75. Deakin JF. Depression and antisocial personality disorder: two
contrasting disorders of 5-HT function. J Neural Transm Suppl
2003; 64:79–93.
76. Roggenbach J, Muller-Oerlinghausen B, Franke L. Suicidality,
impulsivity and aggression – is there a link to 5HIAA concentration
in the cerebrospinal fluid? Psychiatry Res 2002;
113:193–206.
77. Wikander I, Sundblad C, Andersch B et al. Citalopram in premenstrual
dysphoria: is intermittent treatment during luteal
phases more effective than continuous medication throughout
the menstrual cycle? J Clin Psychopharmacol 1998; 18:390–8.
78. Artigas F, Romero L, de Montigny C et al. Acceleration of the
effect of selected antidepressant drugs in major depression by
5-HT1A antagonists. Trends Neurosci 1996; 19:378–83.
79. Hoyer D, Clarke DE, Fozard JR et al. International Union of
Pharmacology classification of receptors for 5-hydroxytryptamine
(serotonin). Pharmacol Rev 1994; 46:157–203.
80. Caliendo G, Santagada V, Perissutti E et al. Derivatives as
5HT1A receptor ligands – past and present. Curr Med Chem
2005; 12:1721–53.
81. Anguelova M, Benkelfat C, Turecki G. A systematic review of
association studies investigating genes coding for serotonin
receptors and the serotonin transporter: I. Affective disorders.
Mol Psychiatry 2003; 8:574–91.
82. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment
of depressive and anxious states: focus on novel therapeutic
strategies. Therapie 2005; 60:441–60.
83. Gershon MD. Review article: serotonin receptors and transporters
– roles in normal and abnormal gastrointestinal motility.
Aliment Pharmacol Ther 2004; 20:S3–14.
84. Gandara DR, Roila F, Warr D et al. Consensus proposal for
5-HT3 antagonists in the prevention of acute emesis related to
highly emetogenic chemotherapy. Dose, schedule, and route of
administration. Support Care Cancer 1998; 6:237–43.
85. Pucadyil TJ, Kalipatnapu S, Chattopadhyay A. The serotonin1A
receptor: a representative member of the serotonin receptor
family. Cell Mol Neurobiol 2005; 25:553–80.
86. Graeff FG, Guimaraes FS, De Andrade TG et al. Role of 5-HT in
stress, anxiety, and depression. Pharmacol Biochem Behav 1996;
54(1):129–41.
NEUROTRANSMITTER PHYSIOLOGY 79
87. Jenike MA, Rauch SL, Cummings JL et al. Recent developments
in neurobiology of obsessive-compulsive disorder. J Clin
Psychiatry 1996; 57:492–503.
88. Charney DS. Neuroanatomical circuits modulating fear and
anxiety behaviors. Acta Psychiatr Scand Suppl 2003; 417:38–50.
89. Meguid MM, Fetissov SO, Varma M et al. Hypothalamic
dopamine and serotonin in the regulation of food intake.
Nutrition 2000; 16:843–57.
90. Dugovic C. Role of serotonin in sleep mechanisms. Rev Neurol
(Paris) 2001; 157:S16–19.
91. Giuliano F, Clement P. Physiology of ejaculation: emphasis on
serotonergic control. Eur Urol 2005; 48:408–17.
92. Hirschfeld RM. History and evolution of the monoamine hypothesis
of depression. J Clin Psychiatry 2000; 61 (Suppl 6):4–6.
93. Schechter D. Estrogen, progesterone, and mood. J Gend Specif
Med 1999; 2:29–36.
94. Schneider LS, Small GW, Hamilton SH et al. Estrogen replacement
and response to fluoxetine in a multicenter geriatric
depression trial. Fluoxetine Collaborative Study Group. Am J
Geriatr Psychiatry 1997; 5:97–106.
95. Klaiber EL, Broverman DM, Vogel W et al. Individual differences
in changes in mood and platelet monoamine oxidase (MAO)
activity during hormonal replacement therapy in menopausal
women. Psychoneuroendocrinology 1996; 21:575–92.
96. Magos AL, Brewster E, Singh R et al. The effects of norethisterone
in postmenopausal women on oestrogen replacement
therapy: a model for the premenstrual syndrome. Br J Obstet
Gynaecol 1986; 93:1290–6.
97. Spinelli MG. Depression and hormone therapy. Clin Obstet
Gynecol 2004; 47:428–36.
98. Roca CA, Schmidt PJ, Smith MJ et al. Effects of metergoline on
symptoms in women with premenstrual dysphoric disorder. Am
J Psychiatry 2002; 159(11):1876–81.
99. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion
aggravates premenstrual syndrome. J Affect Disord 1994;
32(1):37–44.
100. Taylor DL, Mathew RJ, Ho BT et al. Serotonin levels and platelet
uptake during premenstrual tension. Neuropsychobiology 1984;
12:16–8.
101. Rapkin AJ, Edelmuth E, Chang LC et al. Whole-blood serotonin
in premenstrual syndrome. Obstet Gynecol 1987; 70:533–7.
102. Rapkin A, Chang LC, Reading A. Tryptophan loading test in
premenstrual syndrome. J Obstet Gynecol 1989; 10:140–4.
103. Rasgon N, McGuire M, Tanavoli S et al. Neuroendocrine
response to an intravenous L-tryptophan challenge in women
with premenstrual syndrome. Fert Steril 2000; 73(1):144–9.
104. Dimmock PW, Wyatt KM, Jones PW et al. Efficacy of selective
serotonin-reuptake inhibitors in premenstrual syndrome: a systematic
review. Lancet 2000; 356:1131–6.
105. Wyatt KM, Dimmock PW, O’Brien PM. Selective serotonin
reuptake inhibitors for premenstrual syndrome. Cochrane
Database Syst Rev 2002; 4:CD001396.
106. Sanacora G, Mason GF, Rothman DL et al. Increased occipital
cortex GABA concentrations in depressed patients after therapy
with selective serotonin reuptake inhibitors. Am J Psychiatry
2002; 159:663–5.
107. Bhagwagar Z, Wylezinska M, Taylor M et al. Increased brain
GABA concentrations following acute administration of a selective
serotonin reuptake inhibitor. Am J Psychiatry 2004; 161:368–70.
108. Kaura V, Ingram CD, Gartside SE, Young AH, Judge SJ. The
progesterone metabolite allopregnanolone potentiates GABA(A)
receptor-mediated inhibition of 5-HT neuronal activity. Eur
Neuropsychopharmacol 2007; 17(2):108–15.
109. Gulyas AI, Acsady L, Freund TF. Structural basis of the cholinergic
and serotonergic modulation of GABAergic neurons in the
hippocampus. Neurochem Int 1999; 34:359–72.